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Introduction
For years, collaborative consortia have vastly increased sample sizes for genome-wide association studies (GWAS). However, worldwide sample size is finite, and data on clinically important quantitative phenotypes is currently limited, largely due to high costs of deep phenotyping and lacking harmonization of assessment scales and conditions across studies. Nevertheless, quantitative phenotypes are especially valuable for understanding underlying biological mechanisms and between-patient heterogeneity. Hence, complementary to increasing sample size, new approaches and strategies that advance the exploitation of existing genome-wide data are highly desirable.
To gain power and identify underlying mechanisms, recently single-marker tests have been replaced by joint statistics on biological units ( Subramanian et al., 2005; Wang et al., 2007 ) . Joint statistics greatly reduce the multiple-testing burden and may increase power by aggregating association signals from multiple functionallyrelated loci. Many pioneering approaches have aggregated single-SNP GWAS p -values into enrichment statistics for genes or pathways ( Wang et al., 2010 ) . However, unbiased scoring often necessitates time-consuming permutation procedures, since genes and pathways differ in numbers of SNPs, gene length, gene number and linkage disequilibrium (LD)-patterns. Alternatively, SNPs may be aggregated into polygenic risk scores that serve for association testing or trait prediction ( Dudbridge, 2013 ) . Risk scores reduce the model space: they collapse multiple SNPs into a single score with a priori assumptions on the selection and weighting of contributing SNPs ( Dudbridge, 2013 ) . A third set of methods provide actual joint tests of SNPs at the individualdata level. Among them, the kernel score test SKAT ( Schaid, 2010 ) is very powerful for a broad range of genetic architectures, computationally convenient, and yields exact p -values.
Whereas LD is a nuisance for most statistics, SKAT can exploit LD to increase power compared to single-marker tests ( Schifano et al., 2012 ) to the extent that testing LDblocks with SKAT is especially powerful . Since SKAT is a joint test, power increases with cumulative association strength and the ratio between sample size and number of jointly tested SNPs. Therefore, tag SNPs may provide higher power than a denser common SNP panel of the same region . Whereas association strengths and available sample sizes depend on studied phenotypes, sizes of tested SNP sets are the JID: NEUPSY [m6+; November 29, 2018; 6:56 ] analysts' choice. Of all 284 human pathways listed in the KEGG ( Kanehisa and Goto, 2000 ) database at the time of download, only 9.5% contained fewer than 500 SNPs of a typical GWAS marker panel, but 47% of the pathways contained more than 2000 SNPs, and the longest pathway contained around 14,500 SNPs. For clinically important phenotypes however, primary studies or even worldwide samples with comparable phenotyping may encompass only a few thousand subjects. In these instances, power likely differs profoundly between short and long pathways, whereas smaller biological units provide stable power. Note also that pathways may share genes and genes may share SNPs, thus yielding partially overlapping test sets. Herein, we leverage the observed enrichment of small p -values across GWAS among SNPs linked with specific functional elements ( Schork et al., 2013 ) . We a priori identify and test only LD-blocks containing specific functional SNPs, considering these regions putatively relevant in a hypothesis-driven GWAS. A variety of classes of putative functionality of SNPs may be used for selecting genomic regions of interest a priori . Herein, we chose to use non-synonymous coding SNPs (nsSNPs) and no other functional information, as currently nsSNPs can be most reliably predicted ( Li and Wei, 2015; Saunders and Baker, 2002 ) and many genes implicated with BD susceptibility ( Hou et al., 2016 ) , the disorder of interest herein, are protein coding. Hence the presented analysis focused on LD-blocks that overlap with protein-coding sections of the genome, with the extension that exploiting LD putatively may include additional information from SNPs with other functionalities as well. The testing of LD-blocks fully capitalizes on SKAT's advantages. In addition, we improved sensitivity and specificity to detect consistent genetic effects across studies by employing an extension of SKAT for cross-study analysis of individual-level data (mega-analysis).
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As proof of concept, we demonstrate the success of this f unctionally-i nformed e fficient r egion-based test s trategy (FIERS) to uncover genetic risk factors for functional outcome in bipolar disorder (BD) in two independent studies, Genetic Information Association Network ( GAIN) ( Smith et al., 2009 )/ Translational Genomics Research Institute (TGen) study ( Smith et al., 2011 ) , United States, and the Bonn-Mannheim (BOMA) study ( Cichon et al., 2011; Fangerau et al., 2005 ) , Germany, comprising 1592 patients. BD is among the 20 leading causes of disability worldwide ( Vos et al., 2012 ) and genetic factors contribute to BD susceptibility ( Bienvenu et al., 2011; Charney et al., 2017 ) . However, functional outcome of BD is highly variable. While some patients with a mild course of BD experience hardly any restrictions in work or personal relationships between illness episodes, an estimated 30-60% suffer from substantial impairment up to the point of disability ( Sanchez-Moreno et al., 2009 ) . Apart from severe socio-economic consequences, impaired functional outcome also implies a reduced perceived quality of life of patients ( Sum et al., 2015 ) . Several socio-demographic, clinical and cognitive factors associate with impaired functional outcome in BD (for an overview see Gade et al., 2015; Reinares et al., 2013; Solé et al., 2018 ) . The knowledge of these factors and of their interplay is critical for optimizing individualized treatment ( Reinares et al., 2013 ) . Along the same line, it is of utmost importance to gain deeper insights into the biological underpinnings of betweenpatient heterogeneity of functional outcome of BD.
Heritability and familial clustering of reduced global ( Savage et al., 2012; Vassos et al., 2008 ) , social ( Schulze et al., 2006 ) , and occupational ( Potash et al., 2007 ) functioning in families of patients with schizophrenia ( Savage et al., 2012; Vassos et al., 2008 ) or BD ( Potash et al., 2007; Schulze et al., 2006 ) suggest genetic influences. Furthermore, Global Assessment of Functioning (GAF; DSM-IV Axis V) was lower in healthy carriers of neuropsychiatric copy-number-variants compared to non-carriers ( Stefansson et al., 2013 ) . We present here the first genomic study of functional outcome of BD. While BD has an episodic character, most patients experience longer times outside of severe acute manic or depressive episodes than within. Consequently, FIERS was employed to analyze GAF assessed during outpatient treatment, as important cross-diagnostic indicator of overall course and severity of psychiatric disorder.
Experimental procedures

Study participants
Data were provided by the GAIN / TGen study, United States ( Smith et al., 2009 ( Smith et al., , 2011 , and the BOMA study, Germany ( Cichon et al., 2011; Fangerau et al., 2005 ) . All participants gave written informed consent prior to study participation. Study protocols were approved by the respective institutional review boards and in accordance with the 1964 Declaration of Helsinki. For the BOMA sample, summary statistics can be accessed via the Psychiatric Genomic Consortium ( http://www.med.unc.edu/pgc/ ) and individual data by contacting the Institute of Psychiatric Phenomics and Genomics, University Hospital, LMU Munich, Germany (Thomas G. Schulze). GAIN/TGen data can be obtained by contacting the Bipolar Genome Study (John R. Kelsoe). GAIN genotypes are also available at the database of Genotypes and Phenotypes (phs000017.v3.p1) .
From GAIN/TGen , we analyzed 1081 adults of European American ancestry diagnosed with BD according to DSM-IV criteria who had GAF scores. GAIN/TGen provided imputed genome-wide genotypes (see Smith et al., 2009 Smith et al., , 2011 . Patient age ranged from 17 to 77 years (mean ± sd: 43 ± 12 years), duration of illness from 0.5 to 64 years (mean ± sd: 24 ± 13 years), and 34.9% ( n = 377) of participants were men. Diagnoses were obtained based on the Diagnostic Interview for Genetic Studies (DIGS) ( Nurnberger et al., 1994 ) and review of available family history and medical records through a best estimate procedure.
BOMA participants had minimal illness duration of 6 months and were recruited for the purpose of genetic studies ( Fangerau et al., 2005 ) from consecutive hospital admissions at the Central Institute of Mental Health, Mannheim and the Department of Psychiatry, University of Bonn, Germany. Diagnoses were established by the German version of the Structured Clinical interview for DSM-IV-TR Axis I Disorders (Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision, SCID-I) ( First et al., 2002; Wittchen and Fydrich, 1997 ) . We analyzed 511 adult inpatients with a lifetime-diagnosis of BD according to DSM-IV criteria JID: NEUPSY [m6+; November 29, 2018; 6:56 ] and available pre-admission GAF scores and genome-wide genotypes (Illumina: HumanHap550v3, Human610, Human660w) (17). BOMA patient age was comparable to GAIN/TGen and ranged from 18 to 78 years (mean ± sd: 46 ± 13 years), duration of illness was on average shorter (ranging from 0.5 to 61 years, mean ± sd: 17 ± 12 years), and the proportion of men was higher (45.0%, n = 230).
Phenotype
Functional outcome was assessed by the GAF score (DSM-IV Axis V, American Psychiatric Association, 2002 ); details on scale development are described elsewhere ( Endicott et al., 1976; Luborsky, 1962 ) . GAF rates the overall psychological, social and occupational functioning of a subject on a continuum ranging from 1 to 100 ( Luborsky, 1962 ) . Poorer functioning is indicated by lower GAF scores. We analyzed GAF in BD outpatients to target course of disorder outside acute illness episodes. GAF assessments were performed by board-certified psychiatrists or psychologists or psychiatry/psychology trainees at advanced stages in their postgraduate education. In GAIN/TGen , GAF was an average rating over the past (last) month assessed by direct interview of outpatients. Observed scores ranged from 5 to 100 with a median score of 61. In BOMA , the GAF score represents a pre-admission state right before the "current" episode for which the patient received clinical treatment at the time of study interview. Observed GAF scores in BOMA were higher compared to GAIN/TGen and ranged from 25 to 100 with a median score of 80.
Statistical methods -FIERS
FIERS applied a hypothesis-guided filter on the genome, combining two types of prior information: LD structure (from independent reference data) and functional knowledge (from bioinformatic annotation tools). The goal was to a priori identify LD-blocks that contain specific functional elements. In a second step, only these LD-blocks were tested for genotype-phenotype association by employing a generalization of SKAT for cross-study analysis of individual-level data (mega-analysis, details below). This comprised the genotypic information of an LDblock into a single association test, yielding a single pvalue per LD-block, respectively. The employed generalization of SKAT was especially powerful since it methodically optimally exploited all available information; specifically, genomic correlations and consistency (or lack thereof) of putative genetic effects across samples. Finally, to gain additional insight, the detected significant LD-block was examined in detail by single-SNP and haplotype association analyses.
FIERS -step I: hypothesis-guided LD-based selection of genomic regions
Prior information on nsSNPs and LD were obtained for independent population-based reference data from the International Haplotype Map Project (HapMap phase II CEU sample -northern and western European ancestry; 2591820 SNPs, Sabeti et al., 2003 ) and matched to GAIN/TGen and BOMA using hg38 SNP-positions obtained with biomaRt (bioconductor). A listing of nsSNPs was obtained based on SNP rs-identifier numbers from SNPnexus ( Dayem Ullah et al., 2013 ) as predicted by at least one of the widely accepted SIFT ( Kumar et al., 2009 ) or PolyPhen ( Adzhubei et al., 2010 bioinformatics tools , and irrespective of predicted nsSNP impact as this may vary across transcript isoforms. The hg38 start and end positions of LDblocks that contain these functionally annotated SNPs were determined using the default algorithm of Haploview 4.2 ( Barrett et al., 2005 ) such that within assigned LD-blocks at least 70% of all SNP pairs had D' estimates with lower 95% confidence limits above 0.5. The rationale was to detect reasonably strongly correlated SNP sets for subsequent combined evaluation .
GAIN/TGen and BOMA samples were genetically homogeneous and indistinguishable in the four most important principal components (multidimensional scaling analysis, PLINK, data not shown; see Table 1 and Fig. 2 [symbols in bottom panel] for high cross-study similarity of estimated variant frequencies and SNP correlations). Combining external LD information with nsSNP data identified 2957 LD-based blocks for association testing (containing 51,382 SNPs in total) from 410,943 common SNPs available in GAIN/TGen and BOMA after quality control. SNPs were directly typed ( BOMA : HardyWeinberg equilibrium p -value ≥ 10 −5 , call rate ≥ 95%) or came from a larger imputed panel ( GAIN/TGen , see Smith et al., 2009 Smith et al., , 2011 for details on genotyping, quality control and imputation). By construction, GWAS marker panels are LD-pruned. Nevertheless, substantial amounts of LD remain and test strategy FIERS exploits this. The two largest tested LD-based blocks contained 430 and 186 SNPs; all other blocks contained fewer than 79 SNPs. With regards to nsSNP content, 72% of the tested LD-based blocks contained a single nsSNP, 28% contained at least two, with a maximum of 26 nsSNPs in a block.
FIERS -step II: region-based cross-study analysis of individual-level data
PLINK and R (version 3.2.2) were used for statistical analyses. All p-values reported are two-sided. Genetic association screening was performed for the full sample ( quantitative GAF ). Additionally, subjects who had GAF values in the lowest versus highest sample quartile were compared ( GAF extremes ). All analyses were adjusted for fixed effects of sex and duration of illness ( Gade et al., 2015 ) . Putative functional LD-based blocks were tested with SKAT in each study ( GAIN/TGen, BOMA ) and in cross-study analyses (mega-analysis of individual-level data; quantitative GAF : linear model, adjusting for between-study differences of GAF values by a random effect ; GAF extremes : logistic model, adjusting for between-study differences of GAF values by the additional covariate study ). Mega-analysis of individual-level data within SKAT assumed common SNP effects across studies and a linear kernel on minor allele dosages (additive model) with beta -density SNP-weights Beta (MAF,0.5,0.5) that depend on the minor allele frequency (MAF) of SNPs. This choice of kernel and SNP-weights ensured robust power for detecting genetic main effects . Mega-analysis increased the power ( sensitivity ) for detecting reproducible genetic effects as it combined concordant effects across stud- JID: NEUPSY [m6+; November 29, 2018; 6:56 ] b Displayed are single-SNP analyses of additive minor allele effects on functional outcome for the five most strongly associated SNPs and the enclosed nsSNP rs11854184 in the significant LD-block. Analyses within studies are adjusted for sex and illness duration. Studies were meta-analytically combined by Fisher's p -value pooling. A protective minor allele effect is indicated by a positive regression coefficient beta > 0 ( quantitative GAF , linear model) and odds ratio OR < 1 (contrast between GAF extremes , logistic model); beta < 0, OR > 1 for risk minor alleles. Minor allele dosages of all five strongly associated SNPs are pairwise strongly positively correlated, and negatively correlated to the minor allele dosage of putative nsSNP rs11854184 .
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c Individual best-estimate haplotypes were nonambiguous on the last three positions and grouped accordingly. The three most frequent haplotype groups had the identifying nucleobase combinations GCC, ATT, GTC at rs586758, rs2086256, rs1904317; nucleotide base combinations at rs4474633, rs11854184, rs2413930 varied (indicated by * * * ). For haplotype groups, an additive haplotype effect on functional outcome was tested in each study, with adjustment for sex and illness duration. Effects (beta, OR) are specified per haplotype copy. A protective haplotype effect is indicated by a positive regression coefficient beta > 0 ( quantitative GAF , linear model) and odds ratio OR < 1 ( GAF extremes , logistic model); beta < 0, OR > 1 for risk haplotypes. ies into more powerful common effect estimates. Megaanalysis also increased specificity since discordant effect directions across studies will (partially) cancel into small(er) average effects, which suppresses their detection. SKAT exact p -values were obtained by Davies method ( Davies, 1980 ) . For the 2957 SKAT tests performed, the multipletesting adjusted significance threshold was α = 1.7 × 10 −5 (Bonferroni).
FIERS -step III: detailed insight into significant regions
For the 44 SNPs in the detected significant LD-block, single-SNP association tests were performed within studies and meta-analytically combined between studies by Fisher's p -value pooling ( Fisher, 1925 ) . Furthermore, individual bestestimate haplotypes on the five most strongly associated SNPs and an enclosed nsSNP were determined with PLINK. Haplotype association was analyzed within studies assuming an additive model of the effect of a haplotype or group of haplotypes, combining results meta-analytically across studies by Fisher's p -value pooling.
Results
FIERS tested 2957 putatively relevant LD-based regions. Fig. 1 displays Manhattan-like plots of SKAT-derived p -values from cross-study mega-analysis of individual-level GAIN/TGen and BOMA data. SNP correlations within LDbased blocks were subsumed by SKAT tests. Hence SKAT tests of LD-based blocks are largely independent of one another. The traits quantitative GAF (all subjects) and GAF extremes (lowest versus highest study quartile) both identified the same significant LD-block on chromosome 15 (hg38: chr15:48965004 -49464789 bp; quantitative GAF p mega = 1.3 × 10 −5 , GAF extremes p mega = 5.6 × 10 −6 ). Of the 44 SNPs contained in this associated LD-block (see Supplement for summary statistics), 26 had consistent single-SNP effects across studies and meta-analysis p -values p meta < 0.05 for both traits (Fisher's p -value pooling of studies). Eighteen of these SNPs even had p -values p study < 0.05 in both studies and traits ( Fig. 2 , top and middle panel) . The five top-ranked SNPs ( p meta < 5 × 10 −5 , Table 1 ) have strongly positively correlated minor allele dosages ( r > 0.67); rs586758 and rs1904317 are nearly synonymous ( r = 0.998). In the vicinity lies a nsSNP (rs11854184); its minor allele dosage is negatively correlated with that of the five top-ranked SNPs (range = −0.25 > r > −0.34). Individual best-estimate haplotypes on these six SNPs (estimated with PLINK) were nonambiguous on the last three positions and grouped accordingly. This revealed a protective haplotype group ( * * * GCC, quantitative GAF: p meta = 1.1 × 10 −5 , GAF extremes: p meta = 4.6 × 10 −6 ) and a risk haplotype group ( * * * ATT, quantitative GAF: p meta = 2.4 × 10 −5 , GAF JID: NEUPSY [m6+; November 29, 2018; 6:56 ] Fig. 2 Consistent effect strength across BD outpatient samples. In the associated LD-block hg38: chr15:48965004 -49464789 bp, estimated minor allele effects were consistent across studies (US: GAIN/TGen , GER: BOMA ) for quantitative GAF (top, additive effect per minor allele) and GAF extremes (middle, multiplicative effect per minor allele; within-study single-SNP analyses, adjusted for sex and illness duration). Results are displayed for 18 SNPs that had p -values p study < 0.05 in each study and for nsSNP rs11854184 (square). Sign of effect estimates (risk: beta < 0, OR > 1; protective: beta > 0, OR < 1) corresponds to the correlation r of minor allele dosages (bottom panel, solid line) with CTCF binding site rs586758 (diamond). The latter is part of the discovered rs586758 -rs2086256 -rs1904317 haplotype (vertical lines, hg38: chr15:49216375 -49270069 bp) and yielded the strongest association evidence among the 5 top-ranked SNPs ( p meta < 5 × 10 −5 , Table 1 [m6+; November 29, 2018; 6:56 ] extremes: p meta = 2.0 × 10 −6 , Fisher's p -value pooling of studies). Between-study consistency of haplotype association is displayed in Table 1 . A consistent reduction or increase of the risk of poor GAF, respectively, was also observed in all members of the two haplotype groups that were frequent enough for separate association testing (data not shown).
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Discussion
Functional outcome in outpatient care is an important crossdiagnostic indicator for course of psychiatric disorder, clinically highly relevant, and highly variable in BD. To the best of our knowledge, this is the first SNP-based investigation into the genetic basis of GAF in outpatient care. Despite moderate sample size, we identified a significant genomic region by introducing the efficient test strategy FIERS. Plausibility of our finding on chromosome 15 (hg38: chr15:48965004 -49464789 bp) is supported by consistency of effect strength between independent BD patient samples ( Fig. 2 ) and between genotyped ( BOMA ) and imputed SNPs ( GAIN/TGen ). Moreover, further underlining plausibility, the association evidence centers at a functional SNP, and the associated region overlaps with and lies in the vicinity of genes that are relevant for neuronal differentiation and function (see below).
Single-SNP and haplotype analyses indicate that nsSNP rs11854184 is not likely responsible for the association. The reduced power of rs11854184 compared to the top-ranked SNPs ( Table 1 ) cannot sufficiently be explained by its lower minor allele frequency. In contrast, rs586758 displayed the strongest single-SNP association, was part of the discovered haplotypes (G/A position) and is a CTCF binding site ( Cunningham et al., 2015 ) . CTCF sites regulate groups of genes within a chromatin domain.
GAF is not a measure of cognition and may deteriorate in psychiatric disorder for several reasons as it comprises social, occupational, and psychological functioning into a single score. Nevertheless, functional outcome and degree of cognitive impairment are significantly associated in BD and schizophrenia patients ( Bowie et al., 2010 ) . Furthermore, GAF scores and cognitive performance were lower in healthy carriers of neuropsychiatric copy-number-variants compared to non-carriers ( Stefansson et al., 2013 ) . The novel associated haplotype reported herein is located in the promoter flanking region of the COPS2 gene (COP9 signalosome subunit 2, also known as TRIP15, CSN2, ALIEN ), near microRNA4716 as plausible biological candidates. COPS2 is involved in cell cycle regulation and DNA repair, mediates gene silencing, and participates in modulating hormone response and cell proliferation ( Papaioannou, 2007 ) . Moreover, functional studies demonstrated that COPS2 plays crucial roles in neuronal differentiation and development as well as in maintaining neuronal functions ( Akiyama et al., 2003; Chaerkady et al., 2011 ) . Adjacent to the significantly associated LD-block, three additional genes are of interest: upstream EID1 (EP300 interacting inhibitor of differentiation 1) which influences synaptic plasticity and memory function and SHC4 (Src homology 2 domain containing family member 4, also known as ShcD ) which contributes to the regulation of neuronal function through mediation of the tyrosine kinase receptor TrkB downstream signaling pathway ( You et al., 2010 ) . Downstream, gene DTWD1 (DTW domain containing 1) has previously been implicated in a pharmacogenomics study on side-effects of antidepressant treatment ( Clark et al., 2012 ) . Hence it is conceivable that DTWD1 regulation through CTCF binding at rs586758 might alter GAF by altering side-effects of psychopharmacological medication and hence medication adherence.
A particular strength of this study is the test strategy. FIERS contributes to more powerful analyses of existing genome-wide data in general and even enables successful genomic analyses of moderately sized samples. Using general prior knowledge on putative function and LD, FIERS better focused association screening on relevant parts of the genome which greatly reduced the number of statistical tests performed. Across GWAS, small p -values are especially enriched among SNPs that are in LD with specific functional elements ( Schork et al., 2013 ) . FIERS exploits this by jointly testing SNPs within LD-based regions opposed to only testing functionally annotated SNPs. Among the variety of functional annotations that may be used to select LD-blocks a priori, nsSNPs have been most extensively validated so far . Currently, SIFT and PolyPhen provide one of the most widely accepted and accurate ( Saunders and Baker, 2002 ) annotations (nsSNPs) whereas it is still difficult to annotate and predict non-coding SNPs ( Li and Wei, 2015 ) . Analyzing nsSNP-containing LD-blocks focused this analysis on proteincoding regions of the genome with the extension that exploiting LD putatively included additional information from SNPs with other functionalities as well.
A further strength of this investigation is cross-study mega-analysis, i.e. joint analysis of individual-level data across studies within SKAT. With appropriate covariateadjustments, mega-analysis uses the data most efficiently and yields the greatest power. Mega-analysis within SKAT assumed concordant SNP effects across studies. This increased sensitivity for detecting replicable genetic effects and increased specificity by suppressing detection of discordant effects. In comparison, meta-analysis by Fisher's p -value pooling of separately analyzed covariate-adjusted studies was less sensitive and less specific but confirmed the reported significance on chromosome 15, albeit with lower power (data not shown). If mega-analysis should become infeasible (e.g., because studies have different covariates to accommodate or individual-level data cannot be shared), SKAT score statistics may also meta-analytically, i.e. on the level of summary statistics, account for between-study concordance of SNP effects ( Lee et al., 2013 ) .
Mandatory for power of any statistical method is that size of the unit of analysis (LD-block, gene, pathway) and model complexity (main effects, genetic interactions) are appropriate in relation to available sample size. Although large from a clinical perspective, available sample size was a study limitation. We mastered this challenge by testing putatively functionally relevant LD-blocks for main effects. For larger samples, natural extensions are analyzing genes or pathways and allowing for genetic interactions ( Liu et al., 2007 ) . In general, summary statistics on biological units either use select representative SNPs ( Li et al., , 2012 or aggregate association evidence from all contained SNPs. Aggregation is easily, exactly, and powerfully accomplished JID: NEUPSY [m6+; November 29, 2018; 6:56 ] by SKAT on individual-level data. In contrast, tedious corrections for SNP correlations are required when aggregating single-SNP p -values, e.g. by Fisher combination test ( de Leeuw et al., 2016; Li et al., 2011 ) . Other p -value based joint tests such as count-based (SNP-ratio or hypergeometric test) and rank-based (Kolmogorov-Smirnov) enrichment statistics suffer similar drawbacks as the Fisher combination test but with lower power ( de Leeuw et al., 2016 ) . Using representative SNPs instead of fully aggregating all evidence is more powerful only when causal SNPs are greatly outnumbered within tested SNP sets or when causal SNPs cannot share association signals well with other SNPs, e.g., due to low minor allele frequency ( Li et al., 2012 ) . Analogously, single-SNP tests may be more powerful than aggregate tests if associations are strong but involve very few SNPs only ( Chen et al., 2014 ) . Otherwise, SKAT is very often among the most powerful methods, and is robustly powerful for a broad range of genetic architectures (see below) ( Chen et al., 2014; Li et al., 2012 ) . Since SKAT tests combine individual-level information of multiple SNPs and their correlations, they exploit most of the information used in genotype imputation -without doing imputation ( Howey and Cordell, 2014 ) . SKAT can also analyze sequence and rare variants Wu et al., 2011 ) . However, LD should always be estimated on sufficiently frequent SNPs to avoid premature division of LD-blocks. As a self-contained test ( de Leeuw et al., 2016 ) , SKAT evaluates whether any of the jointly tested SNPs associates with a trait of interest. Aggregation of associations (multiple loci, pathway effects) but also relatively localized yet sufficiently strong associations such as polygenes or minor genes within pathways may make SKAT significant. This consideration hardly makes a difference for the LD-block analyses presented herein. However, it highlights that for correct data interpretation, genetic architectures underlying SKAT significances should be examined. So far, the success of psychiatric genetics is largely based on the strategy of founding large consortia for case-control studies. However, data on clinically important quantitative phenotypes is still limited, largely due to high costs of deep phenotyping and lacking harmonization of assessment scales and conditions across studies. Owing to this, a potential limitation of the present investigation is that only two independent studies were available. That significance was reached in the total sample but not in single studies is typical for GWAS which commonly regard consistency of effect estimates across studies ( Fig. 2 ) as additional conclusive evidence. Nevertheless, our consistent finding that rs586758 -rs2086256 -rs1904317 haplotype ATT carriers ( BOMA : 49.2% ± 4.3%, GAIN/TGen : 50.6% ± 3.0%) have lower GAF values would require additional independent validation. Furthermore, no information on medication or medication adherence was available and GAF assessment differed to some extent between studies. GAF was assessed at a time point ( BOMA : pre-admission), or averaged over a period ( GAIN / TGen : past month) during which the state of illness, although sufficiently remitted for outpatient care, may have varied. Statistical analyses were adjusted for between-study differences of GAF values. Nevertheless, differences of GAF assessment might yield phenotypes with slightly different underlying biological mechanisms. This may explain why genetic effects in the associated region ( Table 1 and Fig. 2 ) , while consistent across studies, were slightly stronger in the putatively better remitted BOMA sample compared to GAIN / TGen .
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GAF is an overall rating of a patient's psychological, social and occupational functioning. While clinically highly relevant and commonly used, a single overall score also presents some limitations. Specifically, GAF scores lack information regarding which of the three domains was most impaired and most decisive for individual overall rating. For example, a suicidal person with well-functioning relationships and good performance at his or her job would be assigned a very low GAF score. Hence future research may proceed by operationalizing functional outcome with a more differentiated measure like e.g. the functioning assessment short test (FAST; Rosa et al., 2007 ) . Furthermore, when analyzing GAF scores, it would be of interest to stratify or adjust analyses with respect to concomitant symptom severity. Unfortunately, we did not have sufficient data for this, which is a study limitation.
While low GAF scores may occur in psychiatric patients for clinically different reasons, the generality of the GAF can also be seen as an advantage: GAF is applicable across different psychiatric diagnoses that share a common polygenic background ( Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; Forstner et al., 2017; Purcell et al., 2009 ) and could be an indicator of a more general resilience/ vulnerability factor. Hence it would be of great interest to analyze GAF or other measures of functional outcome also in other psychiatric disorders, such as schizophrenia, and jointly in patients with different psychiatric disorders.
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